# Krystal Biotech Reports Positive Early Trial Data for Gorlin Syndrome Treatment

- URL: https://stocks.freetheai.org/news/krystal-biotech-reports-positive-early-trial-data-for-gorlin-syndrome-treatment-78c63c
- Published: 2026-10-16T14:19:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:KRYS](https://stocks.freetheai.org/symbols/NASDAQ-KRYS)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Krystal Biotech, Inc. (KRYS) announced positive early clinical findings for KB113, an investigational therapy targeting basal cell carcinomas in patients with Gorlin syndrome. In a pilot study involving three adult participants who received six doses over 14 weeks, 83.1% of evaluated lesions showed clinical regression. Notably, responses occurred in both directly injected tumors and non-injected lesions, indicating a potential systemic immune response known as an abscopal effect.

Gorlin syndrome is a genetic condition that causes individuals to develop multiple skin cancers throughout their lives, frequently requiring repeated surgeries that can cause scarring and tissue loss. Krystal Biotech estimates that more than 10,000 people in the United States may live with the condition. The preliminary study results offer initial proof of concept for KB113 as a potential non-surgical treatment option, with the drug proving well tolerated among all participants.

Moving forward, Krystal Biotech has initiated discussions with the U.S. Food and Drug Administration to determine next steps for advanced clinical trials. The company plans to share further details once regulatory plans are finalized. Although further testing in larger patient groups is required to establish safety and efficacy, shares of Krystal Biotech were trading at $319.50, down 3.19% on the day but up 33.9% year to date.

## Key points

- Krystal Biotech announced positive pilot study results for its experimental Gorlin syndrome therapy KB113.
- Over 80% of assessed tumor lesions showed regression, including shrinkage in non-injected tumors.
- All three study participants tolerated the treatment well with no safety issues reported in the trial.
- The company has begun discussions with the FDA regarding advanced clinical development plans.

## Questions and answers

### What were the pilot study results for Krystal Biotech KB113?

In a three-patient pilot study, 83.1% of assessed lesions showed clinical regression following 14 weeks of KB113 treatment. Over half of the lesions shrank by more than 50%, and the treatment was well tolerated.

### What condition does KB113 treat?

KB113 is being developed to treat basal cell carcinomas in patients with Gorlin syndrome, a genetic disorder causing recurring skin tumors.

### What are Krystal Biotech's next steps for KB113?

Krystal Biotech has started discussions with the FDA regarding advanced clinical development for KB113 and plans to update investors after aligning on regulatory plans.